切换至 "中华医学电子期刊资源库"

中华胸部外科电子杂志 ›› 2015, Vol. 02 ›› Issue (01) : 20 -28. doi: 10.3877/cma.j.issn.2095-8773.2015.01.005

所属专题: 文献

论著

术后放疗在胸腺肿瘤治疗中的临床价值:中国胸腺肿瘤研究协作组回顾性研究
杨富1, 傅剑华1,(), 中国胸腺肿瘤研究协作组2   
  1. 1. 510060 广州,广东中山大学附属肿瘤医院胸外科
    2. 中国胸腺瘤协作组
  • 收稿日期:2014-09-20 出版日期:2015-02-28
  • 通信作者: 傅剑华

Clinical value of Postoperative radiation therapy for thymic tumors: a retrospective study from the Chinese Alliance for Research of Thymoma

Fu Yang1, Jianhua Fu1,(), the Chinese Alliance for Research of Thymoma2   

  1. 1. Department of Thoracic Surgery, Sun Yat-sen University Cancer Centre, Guangzhou 510060, China
    2. the Chinese Alliance for Research of Thymoma
  • Received:2014-09-20 Published:2015-02-28
  • Corresponding author: Jianhua Fu
  • About author:
    Corresponding author: Fu Jianhua, Email:
引用本文:

杨富, 傅剑华, 中国胸腺肿瘤研究协作组. 术后放疗在胸腺肿瘤治疗中的临床价值:中国胸腺肿瘤研究协作组回顾性研究[J/OL]. 中华胸部外科电子杂志, 2015, 02(01): 20-28.

Fu Yang, Jianhua Fu, the Chinese Alliance for Research of Thymoma. Clinical value of Postoperative radiation therapy for thymic tumors: a retrospective study from the Chinese Alliance for Research of Thymoma[J/OL]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2015, 02(01): 20-28.

目的

探讨术后放疗在Ⅱ、Ⅲ期胸腺肿瘤中的应用价值。

方法

回顾性分析中国胸腺肿瘤研究协作组(ChART)数据库中1994年4月至2013年3月间的接受手术治疗的Ⅱ期及Ⅲ期胸腺肿瘤病例共870例,最终共有548例符合条件纳入分析,分为术后放疗组(347例)和术后未放疗组(201例)。Kaplan-Meier法分析预后,Cox风险回归模型进行多因素生存分析。

结果

病理类型、Masaoka-Koga分期和手术根治性是胸腺肿瘤主要的预后影响因素。接受根治性手术的胸腺肿瘤患者术后放疗组与未术后放疗组患者的5年、10年生存率分别为87.7%±2.5%、87.8%±4.0%和80.8%±3.6%、83.8%±5.4%,差异无统计学意义(P=0.529,log-rank检验)。接受姑息手术的胸腺肿瘤患者术后放疗组与未术后放疗组的5年、10年生存率分别为73.4%±6.1%、40.4%±15.5%和46.3%±12.4%、40.4%±15.5%,差异有统计学意义(P=0.017,log-rank检验)。胸腺癌患者术后放疗组与未术后放疗组的5年、10年生存率分别为79.3%±3.9%、65.4%±11.1%和49.2%±10.6%、54.5%±13.6%,差异无统计学意义(P=0.054,Breslow检验)。

结论

术后放疗未能改善根治性胸腺肿瘤的预后,但能改善胸腺瘤姑息切除患者的预后,并有改善胸腺癌患者预后的趋势。

Objective

To determine the value of postoperative radiation therapy in stage Ⅱ-Ⅲ thymic tumors.

Methods

The data of patients from the Chinese Alliance of Research for Thymomas (ChART) database between April 1994 and March 2013 were retrospectively analyzed, and the patients were divided into postoperative radiation therapy group and non-postoperative radiation therapy group. The prognosis was estimated with Kaplan-Meier method, and the multi-variate survival analysis was carried out using Cox proportional hazard model.

Results

Pathological type, Masaoka-Koga stage and completion of resection were main prognostic factors of thymic tumors. For the thymic tumor patients with complete resection, the 5-year survival of patients in postoperative radiation therapy group and non-postoperative radiation therapy group were 87.7%±2.5% and 87.8%±4.0%, and the 10-year survival were 80.8%±3.6% and 83.8%±5.4%, respectively(P=0.529, log-rank test). For the thymic tumor patients with incomplete resection, the 5-year survival of patients in postoperative radiation therapy group and non-postoperative radiation therapy group were 73.4%±6.1% and 40.4%±15.5%, and the 10-year survival were 46.3%±12.4% and 40.4%±15.5%, respectively(P=0.017, log-rank test). For the thymic carcinoma patients, the 5-year survival of patients in postoperative radiation therapy group and non-postoperative radiation therapy group were 79.3%±3.9% and 65.4%±11.1%, and the 10-year survival were 49.2%±10.6% and 54.5%±13.6%, respectively(P=0.054, Breslow test).

Conclusions

Postoperative radiation therapy after complete resection does not improve the prognosis of thymic tumors. Postoperative radiation therapy is associated with improved prognosis in patients receiving incomplete resection with thymomas and those with thymic carcinoma.

表1 术后放疗与未术后放疗胸腺肿瘤患者临床特征分析
表2 不同病理类型胸腺肿瘤患者的临床病理特征分析
表3 不同病理分期胸腺肿瘤患者的临床特征分析
表4 胸腺肿瘤患者的单因素生存分析
图1 术后放疗组与未术后放疗组的生存曲线(术后放疗未改善Ⅱ、Ⅲ期胸腺肿瘤患者的预后,P=0.706)
表5 胸腺肿瘤患者术后生存率Cox风险回归模型进行多因素生存分析
表6 分层分析胸腺肿瘤患者术后放疗的作用(x±s)
图3 胸腺瘤和胸腺癌患者术后放疗与未术后放疗的生存曲线。3A为术后放疗未改善A+AB型胸腺瘤患者的预后,P=0.671;3B为术后放疗未改善B型胸腺瘤患者的预后,P=0.422;3C为术后放疗有改善胸腺癌患者预后的趋势,但差异无统计学意义,P=0.054)
[1]
Engels EA. Epidemiology of thymoma and associated malignancies[J]. J Thorac Oncol,2010, 5 (10 Suppl 4): S260-S265.
[2]
Qu YJ, Liu GB, Shi HS, et al. Preoperative CT findings of thymoma are correlated with postoperative Masaoka clinical stage[J]. Acad Radiol, 2013, 20(1): 66-72.
[3]
Detterbeck F, Youssef S, Ruffini E, et al. A review of prognostic factors in thymic malignancies[J]. J Thorac Oncol, 2011, 6 (7 Suppl 3): S1698-1704.
[4]
Detterbeck FC, Zeeshan A. Thymoma: current diagnosis and treatment[J]. Chin Med J (Engl), 2013, 126(11): 2186-2191.
[5]
Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan[J]. Ann Thorac Surg, 2003, 76(3): 878-884; discussion 884-875.
[6]
Rea F, Marulli G, Girardi R, et al. Long-term survival and prognostic factors in thymic epithelial tumours[J]. Eur J Cardiothorac Surg, 2004, 26(2): 412-418.
[7]
Patterson GA, Deslauriers J, Lerut A, et al. Thoracic and esophageal surgery[M]. 3rd ed. Philadelphia: Elsevier, 2008: 1589-1614.
[8]
Tomaszek S, Wigle DA, Keshavjee S,et al. Thymomas: review of current clinical practice[J]. Ann Thorac Surg, 2009, 87(6): 1973-1980.
[9]
Falkson CB, Bezjak A, Darling G, et al. The management of thymoma a systematic review and practice guideline[J]. J Thorac Oncol, 2009, 4(7): 911-919.
[10]
Maggi G, Casadio C, Cavallo A, et al. Thymoma: results of 241 operated cases[J]. Ann Thorac Surg, 1991, 51(1): 152-156.
[11]
Kundel Y, Yellin A, Popovtzer A, et al. Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors[J]. Am J Clin Oncol, 2007, 30(4): 389-394.
[12]
Korst RJ, Kansler AL, Christos PJ, et al. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis[J]. Ann Thorac Surg, 2009, 87(5): 1641-1647.
[13]
Chen G, Marx A, Chen WH, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China[J]. Cancer, 2002, 95(2): 420-429.
[14]
Ogawa K, Uno T, Toita T, et al. Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients [J]. Cancer, 2002, 94(5): 1405-1413.
[15]
Mangi AA, Wain JC, Donahue DM, et al. Adjuvant radiation of stage Ⅲ thymoma: is it necessary? [J] Ann Thorac Surg, 2005, 79(6): 1834-1839.
[16]
Weksler B, Shende M, Nason KS, et al. The role of adjuvant radiation therapy for resected stage Ⅲ thymoma: a population-based study[J]. Ann Thorac Surg, 2012, 93(6): 1822-1828; discussion 1828-1829.
[17]
Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation therapy after complete resection of thymoma has little impact on survival[J]. Cancer, 2009, 115(2): 5413-5420.
[18]
Detterbeck FC, Nicholson AG, Kondo K, et al. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms[J]. J Thorac Oncol, 2011, 6 (7 Suppl 3): S1710-1716.
[19]
陈岗,朱雄增.2004年WHO胸腺上皮肿瘤分类简介与浅评[J].中华病理学杂志,2005,34(12):769-770.
[20]
Beasley MB, Brambilla E, Travis WD. World Health Organization classification of tumors: pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon France: IARC Press, 2004: 146-248.
[21]
Myojin M, Choi NC, Wright CD ,et al. Stage Ⅲ thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study[J]. Int J Radiat Oncol Biol Phys, 2000, 46(4): 927-933.
[22]
Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients[J]. J Thorac Cardiovasc Surg, 1996, 112(2): 376-384.
[23]
Zhu G, He S, Fu X, et al. Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients[J]. Int J Radiat Oncol Biol Phys, 2004, 60(4): 1113-1119.
[24]
Ruffini E, Mancuso M, Oliaro A, et al. Recurrence of thymoma: analysis of clinicopathologic features, treatment, and outcome[J]. J Thorac Cardiovasc Surg, 1997, 113(1): 55-63.
[25]
Shulimzon T, Apter S, Weitzen R, et al. Radiation pneumonitis complicating mediastinal radiotherapy post pneumonectomy[J]. Eur Respir J, 1996, 9(12): 2697-2699.
[26]
Yeoh E, Holloway RH, Russo A, et al. Effects of mediastinal irradiation on oesophageal function[J]. Gut, 1996, 38(2): 166-170.
[27]
Velissaris TJ, Tang AT, Millward-Sadler GH, et al. Pericardial mesothelioma following mantle field radiotherapy[J]. J Cardiovasc Surg (Torino), 2001, 42(3): 425-427.
[28]
Johansson S, Svensson H, Denekamp J. Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients[J]. Int J Radiat Oncol Biol Phys, 2000, 48(3): 745-750.
[29]
Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy[J]. J Clin Oncol, 2004, 22(15): 3139-3148.
[30]
Weksler B, Dhupar R, Parikh V, et al. Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients[J]. Ann Thorac Surg, 2013, 95(1): 299-303.
[31]
Hsu CP, Chen CY, Chen CL, et al. Thymic carcinoma. Ten years’ experience in twenty patients[J]. J Thorac Cardiovasc Surg, 1994, 107(2): 615-620.
[32]
Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: characteristics and long-term outcome[J]. Neurology, 2002, 59(12): 1844-1850.
[33]
Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis[J]. J Clin Oncol, 2004, 22(8): 1501-1509.
[34]
Kondo K, Monden Y. Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan[J]. Ann Thorac Surg, 2005, 79(1): 219-224.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[7] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[8] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要